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The aim of this study was to investigate the expression of the protein tyrosine phosphatases (PTP) PRL-1, PRL-2, and PRL-3 in human
breast cancer and to evaluate its clinical and prognostic significance. PRL-PTP mRNA expression was examined in malignant (n¼7)
and nonmalignant (n¼7) cryoconserved breast tissue samples as well as in eight breast cancer cell lines by RT–PCR. Furthermore,
protein expression of PRL-3 was analysed semiquantitatively by immunohistochemistry in ductal breast carcinoma in situ (n¼135)
and invasive breast cancer (n¼147) by use of tissue microarray technology (TMA). In 24 lymph node-positive patients we selected
the corresponding lymph node metastases for analysis of PRL-3 expression, and a validation set (n¼99) of invasive breast cancer
samples was examined. Staining results were correlated with clinicopathological parameters and long-term follow-up. PRL-3 mRNA
expression was significantly higher in malignant compared to benign breast tissue. For PRL-1 and PRL-2 expression no significant
differences were observed. Staining of TMAs showed PRL-3 expression in 85.9% ductal carcinoma in situ and 75.5% invasive breast
carcinomas. Analysis of survival parameters revealed a shorter disease-free survival (DFS) in patients with PRL-3-positive carcinomas,
and in particular a significantly shorter DFS in nodal-positive patients with PRL-3 overexpressing tumours as compared to PRL-
3-negative breast carcinomas (6677 months (95% CI, 52–80) vs 9779 months (95% CI, 79–115); P¼0.032). Moreover, we found
a more frequent expression of PRL-3 in lymph node metastases as compared to the primary tumours (91.7 vs 66.7%; P¼0.033). Our
results suggest that PRL-3 might serve as a novel prognostic factor in breast cancer, which may help to predict an adverse disease
outcome.
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Protein tyrosine phosphatases (PTPs) play a fundamental role in
regulating diverse proteins that essentially participate in every
aspect of cellular physiologic and pathologic processes (Zeng et al,
1998). The PTP PRL-3, also known as PTP4A3, belongs to a group
of three PTPs (PRL-1, PRL-2, and PRL-3), which share a 76–87%
sequence identity and a unique COOH-terminal prenylation motif
with a PTP-active site signature sequence (Diamond et al, 1994;
Zeng et al, 1998). PRL-1 was the first to be identified, originally as
an immediate early gene, the expression of which was induced in
mitogen-stimulated cells and in regenerating liver, therefore
named ‘protein of regenerating liver’ (PRL) (Mohn et al, 1991;
Montagna et al, 1995). Overexpression of PRL-1 and PRL-2 has
been found to transform mouse fibroblasts and pancreatic
epithelial cell in vitro and to promote tumour growth in nude
mice, suggesting that they might play a role in tumourigenesis
(Diamond et al, 1994; Cates et al, 1996). Migration and invasion
have been shown to be enhanced by PRL-3 and PRL-1 expression
in Chinese hamster ovary cells and overexpression of these
proteins induced metastatic tumour formation in mice (Zeng
et al, 2003). Recent studies showed, that PRL-3 expression is
associated with human ovarian cancer progression (Polato et al,
2005). PRL-3 is overexpressed in metastatic colorectal and gastric
cancer (Miskad et al, 2004), whereas nonmetastatic colorectal and
gastric cancer did not show PRL-3 overexpression (Bardelli et al,
2003; Kato et al, 2004). Also, PRL-3 expression in metastases of
colorectal cancer (CRC) is significantly higher than in the primary
tumour itself or in normal colorectal epithelia (Peng et al, 2004).
Results of these studies suggest that an excess of PRL-3 may play a
key role in the acquisition of metastatic potential of tumour cells.
To date, with respect to breast cancer, there are only data on PRL-3
expression in several breast cancer cell lines available, as recently
reported by Rouleau et al (2006).
Tumour angiogenesis is an important prerequisite of tumour
growth and progression (Folkman, 1995). Among others, one of
the most crucial regulators of angiogenesis is the vascular
endothelial growth factor (VEGF) (reviewed in Morabito et al,
2004). In breast cancer, expression of VEGF is correlated
with angiogenesis and seems to represent a useful prognostic
marker for poor clinical outcome (Yoshiji et al, 1996; Obermair
et al, 1997; de Jong et al, 2001). Parker et al (2004) reported that
PRL-3 is expressed in breast tumour vasculature. In other tumour
entities, evidence of a causative role of PRL-3 in tumour-related
angiogenesis has been demonstrated (Bardelli et al, 2003).
However, to date, there is little data available on expression of
PRL-PTPs in breast cancer and their potential involvement in
angiogenesis.
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sIn this study, we analysed expression of PRL-PTPs in malignant
and nonmalignant breast tissues and characterised several human
breast cancer cell lines with respect to expression of PRL-PTPs.
Furthermore, we evaluated the clinical and prognostic significance
of PRL-3 expression in human breast cancer and its potential role
in tumour angiogenesis.
MATERIALS AND METHODS
Cell lines and tissue samples
Eight human breast cancer cell lines MCF-7, HBL-100, BT-474 (a
gift from C Poremba, Du ¨sseldorf, Germany), SK-BR-3, MDA-MB-
468 (B Brandt, Mu ¨nster, Germany), MDA-MB-453 (A Rody,
Frankfurt, Germany), DU-4475 (C Bremer, Mu ¨nster, Germany),
and MDA-MB-231 (CLS Cell Lines Services, Eppelheim, Germany)
as well as cryoconserved malignant and nonmalignant breast tissue
samples (each: n¼7) were selected for analysis.
RT–PCR analysis
Total cellular RNA from all cancer cell lines and breast tissues was
prepared using the RNeasyt Mini Kit together with the RNase-
Free-DNase Sett (Qiagen Inc., Valencia, CA, USA) to remove
contaminating genomic DNA. Total RNA was reverse-transcribed
with the Advantaget reverse transcription (RT)-for-polymerase
chain reaction (PCR) Kit (BD Clontech, Heidelberg, Germany).
Briefly, 2.5mg of RNA was reverse-transcribed and amplified for 30
cycles (PRL-1), 26 cycles (PRL-2) and 28 cycles (PRL-3) with an
annealing temperature of 601C. Primer sequences for PRL-1 were
50-TACTGCTCCACCAAGAAGCC-30 (forward) and 50-AGGTTT
ACCCCATCCAGGTC-30 (reverse); for PRL-2 50-ACTTTCCCCATCA
CACTCAC-30 (forward) and 50-CCTCTAAATGGCACAATCAAG-30
(reverse) and for PRL-3 50-GGGACTTCTCAGGTCGTGTC-30 (for-
ward) and 50-AGCCCCGTACTTCTTCAGGT-30 (reverse). The
housekeeping gene b-actin was used as an internal control.
Polymerase chain reaction products were subjected to gel
electrophoresis on 1.5% agarose gels under standard conditions
(Samrook et al, 1989). After staining with ethidium bromide, DNA
bands were photographed under UV illumination using a BioDoc
analysing system (Biometra, Go ¨ttingen, Germany). Semiquantita-
tive analysis was carried out using ImageJ software version 1.34
(National Institute of Health, MD, USA). The relative amounts of
PRL-PTP mRNA expression were normalised to b-actin expres-
sion. All experiments were performed in triplicate.
Transient transfection of MCF-7 cells and Western blotting
A polyclonal rabbit-anti-PRL-3 antibody (Zymed, South San
Francisco, CA, USA) was selected for immunohistochemical
analysis. The peptide sequence that Zymed, Inc., selected for the
antibody was specific for PRL-3 and differed from PRL-1 (only 4
a.a. out of 10 a.a. being identical) and PRL-2 (only 2 a.a. out of 10
a.a. being identical, G Hirsch, Invitrogen Ltd, personal commu-
nication). Moreover, Miskad et al (2004) had previously proven by
Western blotting of gastric carcinoma cell extracts that the
antibody is specific for PRL-3. To provide further evidence for
the specificity of the antibody, we probed Western blots of MCF-7
cells overexpressing PRL-3 with the PRL-3 antiserum as follows:
MCF-7 cells were plated in six-well tissue culture plates at 70%
confluency and cultured as previously described (Wu ¨lfing et al,
2005b). After 24h, the cells were transiently transfected with the
control plasmid pcDNA3.1 (Invitrogen, Karlsruhe, Germany) or
with the PTP4A3v1 human phosphatase vector (Stratagene,
Heidelberg, Germany) allowing for the overexpression of PRL-3
under the control of the CMV promoter. The Effectene transfection
reagent (Qiagen, Hilden, Germany) was used following the
manufacturers instructions. At 48h after transfection cells were
lysed and 50mg protein/lane were subjected to SDS–PAGE on 4–
15% gradient gels (Biorad, Munich, Germany) and electrotransfer
to nitrocellulose membranes exactly as described (Sonntag et al,
2005). Immunoblotting was performed by treating nitrocellulose
membranes with blocking buffer (5% skim milk in 0.1% TBS-
Tween (TBST)) for 1h at room temperature, followed by
incubation with the PRL-3 antibody (1:1000 in TBST/5% BSA)
overnight at 41C. After washing in TBST buffer three times, the
membranes were incubated for 1h with horseradish peroxidase-
conjugated anti-rabbit IgG diluted 1:2000 (Cell Signaling Tech-
nology, Beverly, MA, USA) in blocking buffer. The membranes
were washed and treated with enhanced chemiluminescence
detection reagents (Super Signal, Pierce, Bonn, Germany) for
1min, exposed to Hyperfilm-ECL for 45min. The chemolumines-
cence signal on developed films was documented using a BioDoc
analyzing system (Biometra, Go ¨ttingen, Germany).
Patients
To study PRL-3 expression in preinvasive and invasive breast
cancer, in this study tissue samples from 135 patients with ductal
carcinoma in situ (DCIS) and 147 patients with invasive breast
cancer, diagnosed between 1993 and 1997 at the Department of
Gynaecology, University Mu ¨nster, Germany, were analysed. Details
on patients’ characteristics have been described previously
(Wu ¨lfing et al, 2003 and 2005a). In addition, in 24 lymph node-
positive patients we selected the corresponding lymph node
metastases for analysis of PRL-3 expression. For validation of
obtained data a second set of specimens from 99 breast cancer
patients, diagnosed between 1988 and 1990, has been selected.
Follow-up of these patients was evaluated until April 2004. At time
of diagnosis, mean age of the patients was 57.0 months (range: 33–
82 years). Mean disease-free survival (DFS) in this subset was 102.6
months (range, 1–197 months; median, 97.0 months; s.d., 75.2
months), and mean overall survival (OS) was 113.0 months (range
5–197 months; median, 161 months; s.d., 72.3 months). For all
patients informed consent was obtained prior to the study and the
local ethical committee approved use of tumour tissue. Detailed
clinical data regarding diagnosis, histopathological variables,
treatment, and follow-up were collected and stored in a database.
Routinely fixed paraffin-embedded tissue samples of patients were
obtained from the archives of the Gerhard-Domagk-Institute of
Pathology, University of Mu ¨nster, Germany. All DCIS cases were
classified according to the criteria outlined by Holland et al (1994)
considering the nuclear grading and architectural features. Based
on this classification, cases were graduated as low grade (n¼38),
intermediate grade (n¼32), and high grade (n¼62); three cases
could not be graded. With respect to these criteria, cases were
divided into ‘non-high-grade’ (low grade þ intermediate grade)
and ‘high grade’ DCIS. Among the invasive breast carcinomas in
the first tissue microarray technology (TMA)-series (subset 1) 80
(54.4%) were ductal invasive, 33 (22.5%) lobular, 3 (2.0%) tubular,
8 (5.4%) mucinous, 4 (2.7%) medullary, and 19 (12.9%) of mixed
histological differentiation. The second TMA-series (subset 2) used
for validation of results consisted of 64 (64.6%) ductal invasive, six
(6.1%) lobular, one (1.0%) tubular, one (1.0%) scirrhous, and 17
(17.2%) invasive breast carcinomas of mixed histological differ-
entiation. The tissue specimens were classified according to the
Tumour-Node-Metastasis classification of the International Union
Against Cancer, and tumour grade was assigned based on the
criteria of Elston and Ellis (2002). Table 1 summarises the
distribution of Tumour-Node-Metastasis stages and histological
grade in the invasive breast carcinomas in both subsets. To enable
simultaneous analysis of tissues using the same reaction, tissue
microarrays were used for immunohistochemical studies. Prepara-
tion of TMAs was performed as described previously (Wu ¨lfing
et al, 2004). In brief, for each of the cases a representative tumour
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stained slide, at least three morphologically representative regions
were defined for each of the preinvasive and invasive breast cancer
specimens. From these regions cylindrical core tissue specimens
(diameter¼0.6mm) were acquired and precisely arrayed into
several recipient paraffin blocks (20 35mm) using a custom-
built precision instrument (Beecher Instruments, Silver Spring,
MD, USA).
Immunohistochemistry
Consecutive sections of 2–3mm were cut from the TMAs and
processed for immunohistochemistry. Before PRL-3 staining,
specimens were subjected to heat-induced antigen retrieval in a
steamer (Type 3216, Braun, Kronberg, Germany). Immunohisto-
chemical staining for PRL-3 was performed in a multistep
semiautomated procedure (Dako-Autostainer). A polyclonal rabbit
antibody (Zymed, South San Francisco, CA, USA) was used at a
dilution of 1:100. Smooth muscle tissue from appendices known
to express PRL-3 served as positive, omission of the primary
antibody as negative control. After counterstaining with haema-
toxylin, cytoplasmatic and nuclear PRL-3 staining was scored
according to the staining intensity: almost no staining (0),
moderate (1), and strong staining (2). We defined samples with
a moderate or strong immunostaining intensity to have an elevated
PRL-3 expression and thus to be positive. Immunohistochemical
staining for endothelin-A-receptor (ETAR) and VEGF was
performed as described previously (Wu ¨lfing et al, 2004). Staining
results were evaluated semiquantitatively in a blind fashion by
two independent investigators. In case of conflicting results
between the two observers, the higher score was used for statistical
analysis.
Confocal immunofluorescence microscopy
Tissue microarrays were subjected to antigen retrieval as described
in the immunohistochemistry section. The sections were blocked
with PBS/2% goat serum for 1h at room temperature (RT) and
incubated with rabbit-anti-PRL-3 antibody (Zymed) and mouse-
anti-human CD34 antibody (BD Pharmingen, Heidelberg,
Germany) diluted 1:100 in PBS/1% BSA for 16h at 41Ci na
humid chamber. Vascular endothelium and haematopoietic
progenitor cells specifically express CD34. Following four washes
with PBS, the samples were incubated with AlexaFluor 546-
conjugated goat-anti-mouse IgG (Molecular Probes, Eugene OR,
USA, 1:600) and AlexaFluor 488-conjugated donkey-anti-rabbit
IgG (Molecular Probes, 1:600) in the dark for 1h. One TMA was
incubated with secondary antibodies only for control purposes.
Slides were mounted with VectaShield (Vector Labs, Burlingame,
CA, USA). Laser scanning microscopy was performed with a Leica
TCS SL confocal microscope.
Data analysis
T-test was used to test for differences in PRL-PTP expression.
Semiquantitative analysis of staining results was performed in
blind-trial fashion without knowledge of the clinical data for the
corresponding case. Correlations between PRL-3 expression and
clinicopathological parameters were tested for statistical signifi-
cance by w
2 test using SPSS Version 11.0 for Windows. For analysis
of survival data related to PRL-3 expression, Kaplan–Meier
survival estimates were generated and compared by the log-rank
test. Disease-free survival was calculated as the time from the date
of diagnosis to the occurrence of locoregional or distant metastasis
or death. Overall survival was defined as the time from diagnosis to
death from breast cancer. Multivariate analysis was performed
using Cox’s proportional hazards regression model. P-values less
than 0.05 were considered statistically significant.
RESULTS
PRL-PTP mRNA expression in breast tissues and human
breast cancer cell lines
PRL-3 mRNA expression was significantly higher in neoplastic
compared with non-neoplastic breast cancer tissue specimens
(mean 1.01570.156 vs 0.89870.089; P¼0.010). There was a trend
to higher expression in malignant tissue but no significant
difference in the expression of PRL-1 (1.07170.288 vs
0.94070.086; P¼0.080) and no difference with respect to PRL-2
expression (0.97470.154 vs 0.92970.082; P¼0.292) as shown in
Figure 1. All human breast cancer cell lines evaluated in this study
showed expression of PRL-1, PRL-2, and PRL-3 mRNA. Different
expression levels of PRL-PTPs in these cell lines are shown in
Figure 2.
Western blot analysis for specificity of the PRL-3 antibody
For validation of the PRL-3 antibody used for immunohisto-
chemistry, we performed Western blot analysis of PRL-3 up
regulated breast cancer cells. MCF-7 cells were transiently
transfected with a control plasmid and a plasmid overexpressing
PRL-3. Fifty microgram of cell lysate/lane were subjected to SDS–
PAGE and Western blotting using the PRL-3 antibody. A specific
band of about 25kDa was detected in PRL-3 overexpressing MCF-7
cells (Figure 3). The relative molecular weight (Mr) is slightly
higher than the expected 22kDa due to the presence of myc-tags in
the PTP4A3v1 vector. Under the experimental conditions used, the
endogenous level of PRL-3 protein expression in MCF-7 cells was
below the limit of detection.
Protein expression of PRL-3 in preinvasive and invasive
breast cancer, and corresponding lymph node metastases
Expression of PRL-3 was analysed semiquantitatively by immuno-
histochemistry in 135 DCIS and 147 invasive breast carcinomas.
In addition, a validation set of 99 invasive breast cancer samples
was examined. PRL-3 immunoreactivity was mainly located in the
Table 1 Distribution of TMN
a stages and histological grade in the
reported series of breast cancer patients (n¼147 in subset 1 and n¼99 in
subset 2)
Clinicopathological parameter Subset 1 n (%) Subset 2 n (%)
Tumour stage
b
pT1 52 (35.6%) 37 (37.4%)
pT2 54 (37%) 43 (43.4%)
pT3 12 (8.2%) 8 (8.1%)
pT4 28 (19.2%) 10 (10.1%)
Lymph nodes
b
pN0 75 (53.6%) 56 (56.6%)
pN1 53 (37.9%) 25 (25.3%)
pN2 11 (7.9%) 18 (18.2%)
pN3 1 (0.7%) 0 (0%)
Metastasis at diagnosis
c
No 129 (87.8%) 80 (95.2%)
Yes 18 (12.2%) 4 (4.8%)
Histological grade
c
G1 14 (9.5%) 15 (15.3%)
G2 75 (51%) 64 (65.3%)
G3 58 (39.5%) 19 (19.4%)
aTNM, Tumour-Node-Metastasis.
bInformation on pT stage was available in 146 of
147 (99.3%), on pN stage in 140 of 147 (95.9%) patients in subset 1.
cIn subset 2,
information on pM stage was only available in 84 of 99 (84.8%), on histological
grading in 98 of 99 (99.0%) patients.
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scytoplasm, rarely also a nuclear staining was seen in addition.
Moreover, strong PRL-3 staining intensity was observed in breast
tumour vessels, but the stroma was always negative. 116 of 135
(85.9%) of DCIS showed a moderate to strong staining intensity
and were therefore defined as ‘positive’. In invasive breast
carcinomas, 111 of 147 (75.5%) and 79 out of 99 (79.8%) tumour
specimens stained positive for PRL-3. From the 147 breast cancers
studied in subset 1, 80 were ductal invasive breast cancers of which
again 80% (n¼64) were PRL-3 positive. Table 2 provides detailed
information on gradual assessment of PRL-3 staining. 22 of 24
(91.7%) lymph node metastases showed a positive staining for
PRL-3, whereas only 16 (66.7%) of the corresponding primary
tumours were PRL-3 positive. This difference was statistically
significant (P¼0.033). Figure 4 shows samples of PRL-3-negative
and -positive core specimens.
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Figure 1 Boxplots comparing (A) PRL-1, (B) PRL-2, and (C) PRL-3
mRNA expression in non-neoplastic and neoplastic breast cancer speci-
mens. Only PRL-3 showed a significantly higher expression in breast cancer
as compared to normal breast tissue (P¼0.010).
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Figure 2 Expression of PRL-1, PRL-2, and PRL-3 mRNA in different
human breast cancer cell lines. (A) Agarose gel after ethidium bromide
staining. (B) Semiquantitative evaluation of PRL-1, PRL-2, and PRL-3
mRNA expression levels.
Control
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Figure 3 Western blot analysis for specificity of the PRL-3 antibody. A
specific band of about 25kDa was detected in PRL-3 overexpressing MCF-
7 cells.
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sAssociation of PRL-3 expression with clinicopathological
variables
In DCIS, there was no correlation of PRL-3 expression with nuclear
grading. For invasive breast cancer no significant correlation
between PRL-3 expression and common clinicopathological
parameters such as tumour stage, nodal involvement, histologic
grading, hormone receptor status etc. was observed in subset 1
(data not shown). In the series with longer follow-up (subset 2),
patients with PRL-3 overexpressing tumours developed more
frequently distant metastases (w
2 test, P¼0.049). With respect to
angiogenic factors, we observed a close positive correlation
between PRL-3 expression and VEGF (P¼0.042) as well as ETAR
(P¼0.020) expression in invasive breast carcinomas (Figure 5).
Confocal immunofluorescence
Immunofluorescence colabeling of PRL-3 and the vascular
endothelial marker CD34 was performed to proof expression of
PRL-3 not only in breast cancer tumour cells, but also in tumour
vasculature. Colocalisation of PRL-3 with CD34 in breast cancer
tissue was evaluated using confocal laser immunofluorescence.
PRL-3 showed colocalisation with CD34-positive cells and blood
vessels, but was also expressed in CD34-negtative tumour cells, as
shown in Figure 6.
Prognostic value of PRL-3 expression in breast cancer
Analysis of the association of PRL-3 expression with survival was
performed for patients with invasive breast cancer. In subset 1,
patients with PRL-3-positive breast carcinomas showed a trend
towards shorter DFS compared to patients with PRL-3-negative
cancers (8374 months (95% CI, 74–91) vs 8978 months (95% CI,
74–105), respectively). However, this difference was statistically
not significant (P¼0.282). However, in the group of node-positive
breast cancer patients PRL-3 expression was associated with a
significantly worse DFS (6677 months (95% CI 52–80) compared
to patients with PRL-3-negative tumours (9779 months (95% CI
Table 2 Immunohistochemical analysis of PRL-3 expression in DCIS and
invasive breast cancer
DCIS
Invasive breast cancer
Score n( % ) Subset 1 n( % ) Subset 2 n( % )
0 19 (14.1) 36 (24.5) 20 (20.2)
1+ 60 (44.4) 74 (50.3) 63 (63.6)
2+ 56 (41.5) 37 (25.2) 16 (16.2)
Negative (score 0) 19 (14.1) 36 (24.5) 20 (20.2)
Positive (score 1–2) 116 (85.9) 111 (75.5) 79 (79.8)
DCIS, ductal breast carcinoma in situ.
AB C
DE F
Figure 4 Invasive breast cancer specimens from the tissue microarray
with (A) negative, (B) moderate, and (C) strong positive staining reaction
for PRL-3. (D) Strong PLR-3 staining of tumour vessel. (E) PRL-3 negative
and (F) positive lymph node metastases. Magnification 10-fold.
VEGF ETAR
P=0.042 P=0.020
%
Negative
Negative Negative
Expression of PRL-3
Positive
Positive Positive
70.6
29.4 52.3 42.9 62.4
47.7 57.1 37.6
Figure 5 Expression of PRL-3 correlated with VEGF and ETAR
expression, respectively.
PRL-3 CD34 Overlay
A
B
C
Figure 6 Colocalisation of PRL-3 with the vascular endothelial marker
CD34 in breast cancer tissue. Left panels¼PRL-3 staining (green
fluorescent secondary antibody), central panels¼CD34-staining (red
fluorescent secondary antibody), right panels¼merged image, yellow
staining denotes colocalisation; (A) Colocalisation of PRL-3 with CD34-
positive cells forming small blood vessels; (B) colocalisation of PRL-3 with
CD34-positive blood vessels; (C) PRL-3 expression is not restricted to
CD34-positive blood vessels (arrows) but occurs also in CD34-negative
tumour cells (asterisks); bar¼25mm.
PRL-3 in breast cancer
I Radke et al
351
British Journal of Cancer (2006) 95(3), 347–354 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s79–115); P¼0.032). The corresponding Kaplan–Meier curves are
shown in Figure 7. Interestingly, DFS in nodal-positive but PRL-3-
negative patients is comparable to that of nodal-negative patients
(9779 months (95% CI, 79–115) and 94710 months (95% CI,
75–113), respectively). No significant difference was observed
between OS and PRL-3 expression.
Corresponding to our results from subset 1, a trend towards
shorter DFS in PRL-3-positive carcinomas compared to patients
with PRL-3-negative carcinomas was also observed the series of
patients with longer follow-up (subset 2) with a mean DFS of
118711 months (95% CI, 97–139) in PRL-3-positive vs 138718
months (95% CI, 103–172; P¼0.330) in PRL-3-negative patients,
respectively. Since in this subset only three patients with lymph
node involvement had PRL-3-negative tumours, a subgroup
analysis of node-positive patients with respect to PRL-3 expression
was not feasible. There was a trend towards shorter OS in PRL-3-
positive patients in subset 2: 13979 months (95% CI, 121–158) vs
172711 months (95% CI 149–194; P¼0.066), respectively.
DISCUSSION
A number of emerging new prognostic markers of breast cancer
have been investigated. The presence or absence of lymph node
metastasis is still regarded as the most valuable single prognostic
attribute (Goldhirsch et al, 2005). However, additional markers are
needed to facilitate a risk-directed treatment tailored to individual
patients.
The purpose of the present study was to determine whether
the PTPs, in particular PRL-3, could provide additional
prognostic value in breast cancer patients. The PRL-3 mRNA
expression was significantly elevated in neoplastic compared to
normal breast tissue. For PRL-2 and PRL-1 mRNA expression
no significant differences were found. Therefore, at the protein
level, we focused on PRL-3 expression in preinvasive and invasive
breast cancer as well as in corresponding lymph node metastases
using TMA.
PRL-3 protein expression was seen in 75.5% of all invasive
breast cancers and 85.9% of DCIS. The higher expression rate in
DCIS was somewhat surprising but has similarly been shown for
HER2 expression: HER2 representing a marker of poor prognosis
in breast cancer. It is involved in normal breast growth and
development, and overexpression of HER2 seems to play a role in
malignant transformation and tumourigenesis. HER2 was first
reported in preinvasive breast cancer, and higher expression in
DCIS than in IDC has been demonstrated (Ross and Fletcher, 1998;
Menard et al, 2001). The explanation of this phenomenon was, that
HER2-negative IDCs might not derive from DCIS, but develop
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Figure 7 Kaplan–Meier estimates for DFS time and OS with respect to PRL-3 expression and clinicopathological parameters. (A) Disease-free survival
time stratified by PRL-3 expression. (B) Survival curves for the subgroups of patients with nodal-positive invasive breast cancer stratified by PRL-3
expression. (C) Disease-free survival and (D) OS in subset 2, a set of patients with longer follow-up, stratified by PRL-3 expression.
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sfrom another lesion, the atypical ductal hyperplasia (ADH), which
showed no HER2 amplification (Menard et al, 2001). The same
might be the case in PRL-3 expression, but to date, there is no data
on the expression of PRL-3 in ADH.
PRL-3 overexpression has been reported for colorectal, liver,
and gastric cancer (Stephens et al, 2005) and recently for ovarian
cancer (Polato et al, 2005). PRL-3 has been shown to influence
proliferation, migration, and metastasis of cancer cells in vitro and
in vivo (Cates et al, 1996; Wang et al, 2002; Zeng et al, 2003).
Several studies have demonstrated the relevance of tumour
angiogenesis for these particular tumour cell properties (Folkman
and Klagsbrun, 1987; Hanahan and Weinberg, 2000; Alberts, 2002;
Ambler et al, 2003). In a xenograft model PRL-3 expressing
tumours showed a dense formation of tubular structures with
histological similarity to blood vessels. Also, these PRL-3 over-
expressing tumours were highly vascularised. In contrast, the PRL-
3-negative controls did not show these features (Guo et al, 2004).
Therefore, PRL-3 might play a causative role in tumour-related
angiogenesis. Consistently, for breast and CRC PRL-3 over-
expression has been described especially in the tumours endo-
thelial cells (Bardelli et al, 2003; Parker et al, 2004). Vascular
endothelial growth factor is known to be another important factor
for tumour angiogenesis. Vascular endothelial growth factor has
been shown to stimulate the migration of endothelial cells, the
formation of blood vessels in tumours (Ambler et al, 2003) and is
associated with an adverse outcome of breast cancer patients
(Gasparini, 2001). In this study, we found a positive correlation
between PRL-3 and VEGF expression in breast cancer cells.
Moreover, we observed a positive association of PRL-3 expression
with expression of the ETAR, another proangiogenic factor in
breast cancer (Nelson et al, 2003; Wu ¨lfing et al, 2004). To
strengthen the hypothesis that PRL-3 plays a role in tumour
angiogenesis we performed confocal immunofluorescence of PRL-
3 and CD34, a specific marker for endothelial cells, widely used in
microscopic evaluation of tumour angiogenesis (reviewed in
McDonald and Choyke, 2003). We could demonstrate that PRL-3
is expressed in CD34-positive endothelial cells and microvessels as
well as in CD34-negative tumour cells. These findings suggest that
PRL-3 expression may also play an autocrine and paracrine role in
breast cancer angiogenesis.
PRL-3 protein expression previously has been analysed in other
adenocarcinomas, in particular in colorectal and gastric cancer.
For CRC higher PRL-3 gene and protein expression in metastases
than in nonmetastatic tumours and normal colorectal epithelium
were reported (Peng et al, 2004). In gastric, colorectal and ovarian
cancer, PRL-3 expression was associated with tumour stage and
extent of lymph node metastasis (Miskad et al, 2004), and for CRC
a negative prognostic impact with shorter survival was found
(Peng et al, 2004). In vitro, knockdown of PRL-3 in ovarian cancer
cell lines with small interfering RNA resulted in impaired cancer
cell growth (Polato et al, 2005).
In this study, we also analysed expression of PRL-3 in
breast carcinomas and their corresponding lymph node meta-
stases. As shown for other tumour entities, we have found a
significantly more frequent expression of PRL-3 in lymph node
metastases as compared to the corresponding primary tumour.
Moreover, we observed a higher incidence of subsequent distant
metastases in patients with PRL-3 overexpressing breast carcino-
mas. In addition, Rouleau et al (2006) could demonstrate, that
PRL-3 actively promotes invasiveness of MCF-7 cells in vitro.I n
summary, overexpression of PRL-3 might facilitate tumour cells to
invade into lymphatics or vasculature, and therefore being a
prerequisite for development of local lymph node and distant
metastases.
PRL-3 expression seems to adversely influence DFS in breast
cancer patients. We found PRL-3 expression to correlate with
decreased DFS. This negative prognostic impact was in particular
pronounced in lymph node-positive breast cancer patients.
Conversely, patients with PRL-3-negative tumours showed a
significantly longer DFS. Absence of PRL-3 expression even
abrogated the survival difference between node-negative and
node-positive patients. Taking into account that the presence or
absence of lymph node metastases is regarded the most valuable
single prognostic factor, these results are interesting. The relatively
small set of PRL-3-negative tumours in our study (24.5%)
might represent a group of patients with unexpectedly good
prognosis, even in case of lymph node involvement. In patients
with breast cancer, a long observational period is necessary to
discriminate patients with respect to prognosis. The trend
towards an impaired DFS observed in our pilot study was
confirmed in a subsequent study performed for validation of
these findings. This validation set was characterised by a longer
period of follow-up as compared to the initial subset. In this
subset, we found a trend towards a shorter OS in PRL-3-positive
breast cancer patients. The longer follow-up period in this subset
might explain why effects of PRL-3 expression on OS became
detectable only in this subset of patients. There was no correlation
between PRL-3 expression and conventional clinicopathological
prognostic markers.
In view of our findings expression of PRL-3 may facilitate
identification of patients who are at high risk for disease
recurrence (PRL-3-positive tumours) or conversely of patients
who have an unanticipated good prognosis despite lymph
node metastases (PRL-3-negative tumours, respectively). Adjuvant
systemic therapy has been proven to reduce mortality from
breast cancer (EBCTCG, 2005). However, some patients receive
therapy with little or no likelihood of benefit. For example, patients
with early stage, lymph node-negative breast cancer have
approximately 25% risk of dying from breast cancer within 10
years if they do not receive adjuvant treatment, whereas 75%
however, will survive 10 years even without any further treatment
(Chia et al, 2004). Therefore, reliable prognostic markers are
needed to help selecting those patients who most likely benefit
from systemic therapy and need even more intensive treatment
because of high risk of disease recurrence or death. Further studies
are necessary to confirm that the analysis of PRL-3 expression in
breast cancer might help select patients who are at higher risk for
disease recurrence and therefore should receive appropriate
systemic treatment.
Moreover, PRL-3 might be a new therapeutic target. Pentami-
dine, an antileishmaniasis drug with unknown mechanism of
action has been shown to inhibit PRL phosphatases in vitro and
may provide a basis for developing novel PTPase-targeted
therapeutics (Pathak et al, 2002). Also, farnesyltranferase inhibi-
tors are suspected to function not only through inhibition of
members of the Ras oncogene family, but as well through
inhibition of PRL-PTPs (Sebti and Der, 2003).
In summary, we have shown that PRL-3 is expressed in breast
cancer. PRL-3 expression seems to adversely influence disease
outcome, being related to a shorter DFS in breast cancer patients.
Our findings suggest that analysis of PRL-3 expression might serve
as an additional, prognostic factor in breast cancer and could be
useful for choice of risk-adapted, more tailored treatment concepts
for the individual patient.
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